Trial Information

Pediatric brain cancer is relatively rare. However, cancer is the leading cause of death by disease among children in the U.S.  Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.

Plus Therapeutics is developing the REYOBIQ™ (rhenium Re186 obisbemeda) radiotherapeutic for the treatment of rare, frequently fast-growing pediatric brain and spinal cord tumors with a poor prognosis – ependymoma and high-grade glioma (HGG).  The ReSPECT-PBC (Pediatric Brain Cancer) U.S. Phase 1 Clinical Trial is planned to start in 2025.

“Children with brain tumors have limited options & 186RNL (REYOBIQ™) delivered with a minimally invasive procedure could be an important new potential option for these patients.”

Michael G. DeCuypere, MD, PhD, FAANS

Northwestern University Feinberg School of Medicine

Principal Investigators

There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.

Ashley S. Plant, M.D.

Lurie Children’s Hospital of Chicago

SPECIALTIES:  CANCER & BLOOD DISORDERS

Ashley S. Plant, M.D. is an attending physician in neuro-oncology at Ann and Robert H. Lurie Children’s Hospital of Chicago and is an Assistant Professor of Pediatrics at Northwestern University. Dr. Plant received her medical degree from Stanford University School of Medicine. She completed her pediatrics residency at University of California, Los Angeles and her pediatric hematology/oncology fellowship at Dana Farber Cancer Institute/Boston Children’s Hospital. She completed additional training in neuro-oncology at Dana Farber Cancer Institute. Her research focus includes immunotherapy and the immune microenvironment as well as early phase clinical trial design for pediatric brain tumors.

Trial Locations

Please visit this website regularly for updates as new locations are added.

Lurie Children’s Hospital

Chicago, Illinois

What Can You Do Next?

Participating in a clinical trial is an important decision.  If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Request Information

3 + 7 =

News

 
April 9, 2024
 
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
 

November 29, 2023

Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe

  • Presentation titled “Re-186 Radiolabelled NanoLiposomes for Rare Brain and Spinal Cord Tumors”

June 8, 2023

Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

  • Plus Therapeutics announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.

August 21, 2021

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer

June 10, 2021

Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference

Updates

Brain Cancer Awareness Month 2025

Honoring Brain Cancer Awareness Month: Advancing Research, Raising Voices, and Recruiting for Clinical Trials May is Brain Cancer Awareness Month! A time dedicated to elevating the voices of patients, caregivers, and advocates affected by brain tumors. At Plus...

read more

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.